The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.10 - Manufacture of basic pharmaceutical products
100 jobs Number of planned job creations
Announcement Date
11 February 2015
Employment effect (start)
Foreseen end date
Description
The multinational producer of pharmaceutical products, Pfizer, has invested 75 million euro in a production unit creating sterile doses of the pneumococcal vaccine Prevenar 13 at its Puurs facility, creating 100 extra jobs. Employment here has grown from 1,100 employees in 2010 to a scheduled 1,600 employees at the end of 2016.
The managing director indicated that one of the attractions for the US company to invest in Puurs has been the good technical training of employees. The production of this specific vaccine was done to date in the United States.
Sources
11 February 2015: De Standaard
Citation
Eurofound (2015), Pfizer, Business expansion in Belgium, factsheet number 78607, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/78607.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
